Niraparib Offers New Option in Heavily Pretreated Ovarian Cancer

April 17, 2019 7:00 pm

By Dave Levitan

Niraparib showed promising and clinically relevant activity as therapy for heavily pretreated patients with ovarian cancer, according to a new phase II study. This was particularly true among women with homologous recombination deficiency (HRD)-positive tumors.

“Although most … Read more

SGO 2019: Maintenance Rucaparib Effective for All Age Groups in Ovarian Cancer

March 22, 2019 5:00 pm

By Christina Bennett, MS

Rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, was effective as a maintenance therapy across all age groups of patients with recurrent ovarian cancer, according to the results of a post-hoc exploratory analysis of ARIEL3 presented at … Read more

Individualized Dosing Regimen Reduces Side Effects in Ovarian Cancer Maintenance Therapy

March 18, 2019 7:00 pm

By Kristie L. Kahl

Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose, according to a recent analysis

Read more

When PARP Inhibitors Fail in Ovarian Cancer

March 18, 2019 6:00 pm

By Ian Ingram

Study identifies subgroup for whom another go could be worthwhile.

Lack of response to a PARP inhibitor in epithelial ovarian cancer didn’t necessarily mean patients were resistant to all such agents, a small retrospective study indicated.

Among … Read more

PARP Inhibitor Benefit Gets a TWiST in Recurrent Ovarian Cancer

March 17, 2019 6:00 pm

By Ian Ingram

In delaying disease progression in recurrent ovarian cancer, maintenance therapy with the PARP inhibitor niraparib (Zejula) also increased patients’ time without symptoms or toxicity (TWiST), an analysis of the phase III NOVA trial found.

Compared with placebo, … Read more

Cancer Biomarker for PARP Inhibitor Effectiveness Discovered

March 15, 2019 5:00 pm

Since tumors often have unique defects in the DNA damage response (DDR) pathway, identifying the molecular mechanisms that underlie how cells repair various DNA lesions is critical to selecting the appropriate clinical treatments. Inhibitors to poly-(ADP-ribose) polymerase (PARP) are examples … Read more

Drug Target Identified for Chemotherapy-Resistant Ovarian, Breast Cancer

February 4, 2019 5:00 pm

By Tamara Bhandari

Study finds mimic for BRCA genes that could be targeted to improve treatment

People who inherit a faulty copy of the so-called “breast cancer genes” BRCA1 and BRCA2 are at high risk of cancer. About 10 percent … Read more

FDA Approves Lynparza for Maintenance Treatment of BRCA-Mutant Gynecologic Cancers

December 19, 2018 5:00 pm

By Brielle Benyon

The Food and Drug Administration (FDA) approved Lynparza (olaparib) for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a

Read more

Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer

October 25, 2018 1:11 am

By 

Real-world experience of adverse events with the oral PARP inhibitor niraparib in patients with platinum-sensitive recurrent ovarian cancer at a 200 mg daily dose differed from those most commonly seen in the phase 3 clinical trial at … Read more

Ovarian Cancer ‘Breakthrough’ Drug Prevents Disease Returning for Years

October 22, 2018 4:35 pm

By 

A new ovarian cancer treatment dramatically reduces the chances of the disease returning, a study has shown.

Doctors have hailed the results of a “breakthrough” trial which they say opens the possibility that many more women suffering … Read more

BRCA1 Methylation Level May Predict Which Ovarian Cancer Patients Respond to PARP Inhibitors

September 28, 2018 8:37 pm

The extent to which the BRCA1 promoter is methylated could signal an ovarian tumor’s susceptibility to PARP inhibitor treatment, a new study has found.

PARP inhibitor treatment has been effective in treating some patients with high-grade serous ovarian carcinoma with … Read more

New Developments in Ovarian Cancer Treatment Are Showing Promise

September 14, 2018 4:29 pm

Cancer is never an easy foe, but some types are more stubborn than others. Ovarian cancer is one of the hardest to treat.

But there are signs of progress. Several recent studies have used new combination treatment strategies, including a … Read more

The Future of Ovarian Cancer: PARP Inhibition ‘Leading the Way’

July 6, 2018 8:58 pm
By Brielle Urciuoli
PARP inhibitors have made for new and exciting treatment options for ovarian cancer, but there is still much more work to be done, according to Dennis J. Slamon, M.D., Ph.D.

Slamon, who is the director of both

Read more

Olaparib Plus Vistusertib Promising in Early Trial

June 8, 2018 9:48 pm

The combination of the PARP inhibitor olaparib with an mTORC1/2 inhibitor known as vistusertib was tolerable and had promising activity across endometrial, ovarian, and triple-negative breast cancers, according to a phase I trial. Results of the trial (abstract 5504Read more

Scientists Identify Why Some May Be Resistant To PARP Inhibitor Drugs

May 21, 2018 6:33 pm

A team of scientists from the Institute of Cancer Research in London has identified DNA mutations which makes cancer cells resistant to a new class of drugs called PARP inhibitors, used for the treatment of breast and ovarian cancers.

The … Read more

New Immunotherapy Shows Promise Against Ovarian Cancer

April 10, 2018 8:57 pm

Ovarian cancer can be tough to beat, particularly if it returns after initial treatment, but new research offers a glimmer of hope.

One study found that a new targeted “immunotherapy” to treat ovarian cancer that has come back looked promising … Read more

FDA Approves Rubraca for Maintenance Ovarian Cancer Treatment

April 6, 2018 8:05 pm

The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more

SGO 2018: Immunotherapy/PARP Inhibitor Combination Produces Remissions in Ovarian Cancer

April 2, 2018 5:19 pm

A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers … Read more

SGO 2018: Putting PARP Inhibitor Perspectives Into Practice

March 28, 2018 9:28 pm

Achieving consensus on which poly (ADP-ribose) polymerase (PARP) inhibitor to use and when during management of ovarian cancer proved challenging Sunday for 4 oncologists who took attendees through a lively discussion of applying current standards from professional societies to everyday … Read more

7 Key Cancer Trends For 2018

January 3, 2018 6:48 pm

By: Elaine Schattner

I expect progress. Here’s my list of major trends and issues that will affect the lives of cancer patients in 2018:

1. Less chemotherapy

recent report finds that among patients with the most common form of … Read more